BairdPayne Global Pharmaceutical Services, Inc.

About BPG

Mission

BairdPayne Global Pharmaceutical Services, Inc. (BPG) was incorporated in the State of Delaware in 2006 by its founder, Martin McMillan, Ph.D., with the mission to provide an array of quality scientific, engineering, and consulting services relating to x-ray protein crystallography and drug discovery. While targeting startup and small biotechnology companies, BPG provides resources to large, established pharmaceutical companies as well.

Martin McMillan, Ph.D.

Dr. McMillan began his scientific training at Duke University where he graduated Magna cum Laude with a BSEE with Honors degree in 1981. Not just staying close to the electrical engineering curriculum, he consistantly took courses in mathematics, physics, chemistry, and computer science, as well as music performance and german literature. Fluent in german, Dr. McMillan worked on several occasions during college and graduate school with Degussa, AG, at its central research facilities near Hanau, Germany.

Entering Yale University in 1981 as a Gulf Oil Fellow, Dr. McMillan began his graduate work in chemical engineering under the tutelage of Professor Gary Haller in whose laboratory the research centered around the physical chemistry of heterogeneous catalysts. His introduction to x-ray science was with measuring the Extended X-ray Absorption Fine Structure (EXAFS) of metals dispersed on high surface area alumina, silica, and titania oxide supports. The vast majority of this research was carried out at the Cornell High Energy Synchrotron Source (CHESS). While at Yale, Dr. McMillan was elected President of the Graduate & Professional Student Senate in whose capacity he represented the interests of the 5000 graduate and professional students over and against Yale's Administration and the then President of the University, A. Bartlett Giamatti.

After obtaining his Ph.D. in 1987, Dr. McMillan took a post-doctoral fellowship in the Chemistry Department at Cornell University. In the laboratory of Professor Hector Abruña, he worked on developing techniques in surface x-ray scattering off of electrochemical (i.e. solid-solution) interfaces. At the same time he worked on the operations staff at CHESS, where his research was focussed on dynamical x-ray diffraction.

Dr. McMillan accepted a position as a crystallographer at Eastman Kodak in Rochester, New York in 1988. In that capacity, he refined techniques in x-ray powder diffraction of silver halides and collaborated with researchers at the University of Glasgow and Rutherford Appleton Laboratory in developing protocols for structure solution from x-ray powder diffraction data. As well as being the small molecule crystallographer for Kodak, Dr. McMillan also worked with the then Stirling Winthrop Pharmaceutical Division of Eastman Kodak as as a consulting crystallographer on its human rhinovirus (HRV) drug discovery project. At the same time, Dr. McMillan was granted an adjunct faculty position at the Hauptman-Woodward Medical Research Institute in Buffalo, New York where he serves as an advisor to Herbert A. Hauptman, Ph.D., 1985 Nobel Laureate in Chemistry.

In 1997, Dr. McMillan joined 3-Dimensional Pharmaceuticals, Inc. as a protein crystallographer. In that capacity, he worked on a number of drug discovery projects which included thrombin and urokinase plasminogen activator inhibitors. He also ran the in-house x-ray facility and was the project manager for synchrotron radiation research.

After nearly a decade and a half in industry, Dr. McMillan, in 2004, accepted a position at the National Synchrotron Light Source at Brookhaven National Laboratory as the beamline scientist for X-ray Beamline X8C. Once again, acting as a project manager, Dr. McMillan oversaw the day-to-day operations of the beamline as well as contributing to the Protein Crystallography Research Resource (PXRR) as a systems administrator.

Upon the end of his contract with X8C in 2006, Dr. McMillan founded BairdPayne Global Pharmaceutical Services, Inc. (BPG) in order to capitalize on his 25 years experience in x-ray diffraction and crystallography. The goal of BPG is to add value to the portfolios of small and startup biotechnology companies engaging in drug discovery and structural biology while keeping costs and overhead at a minimum.

Dr. McMillan's curriculum vitae is viewable as a pdf file.

This page is best viewed with JavaScript and Java Applet support enabled.

BairdPayne Global Pharmaceutical Services, Inc.

Monday December 01, 2008

About BPG

Mission

Martin McMillan, Ph.D.

home

Sponsored Links